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Introduction
To say that science is about understanding the mysteries 
is not very new. However, even in the relatively dry and 
ordinary  issues  of  statistical  and  genetic  epidemiology 
there  remains  a  lot  of  space  for  a  mystery  to  be  dis­
covered.  During  the  60th  annual  meeting  of  the 
American  Society  of  Human  Genetics  (ASHG),  many 
topics referred to the phenomenon of ‘missing herita­
bility’,  which  was  previously  coined  by  Maher  (Nature 
2008, 456:18­21).
The 60th annual meeting of the AHSG was held on 2­6 
November 2010, at the Walter E Washington Convention 
Center,  Washington,  DC,  USA.  There  were  more  than 
7,200 participants and almost 3,000 presentations at the 
conference, a record­breaking number.
Two lectures at the very beginning of the conference 
highlighted the fact that the meeting was refining plans 
for comprehensive research into common complex human 
diseases  in  the  coming  years.  At  the  pre­conference 
National  Institute  on  Alcohol  Abuse  and  Alcoholism 
symposium  ‘Tightening  the  genotype­phenotype  gap: 
from genetic variation to gene function’, Dr Eric Green 
(Director  of  the  National  Human  Genome  Research 
Institute,  Bethesda,  MD,  USA)  made  a  presentation 
entitled  ‘En  route  to  the  era  of  genomic  medicine’, 
presenting a draft of the strategy for genetic research in 
this  area.  Second,  at  very  beginning  of  the  conference 
itself, Dr Eric S Lander (Broad Institute of Harvard and 
MIT,  Cambridge,  MA,  USA)  presented  ‘The  human 
genome project: a decade later’, which was an overview of 
the achievements and perspectives of human genetics. It 
was  especially  interesting  to  hear  how  the  mystery  of 
‘missing heritability’ could be explained. The key word 
was  ‘interaction’.  Interaction  between  genes,  epistasis, 
may clarify what has been missing in our understanding 
of genetics of complex diseases.
The mystery of the missing heritability
According  to  the  generally  accepted  view,  common 
complex  human  diseases,  such  as  type  1  or  type  2 
diabetes, multiple sclerosis, Alzheimer’s disease, rheuma­
toid arthritis, asthma and many others, are the product 
of at least two types of factor: environmental and genetic 
(heritability).  The  impact  of  the  latter  factor  is  high 
enough  to  bring  these  diseases  to  the  field  of  genetic 
research. However, there is a problem due to uncertain 
patterns of inheritance and relatively low penetrance for 
these diseases. In contrast, Mendelian diseases demon­
strate  more  predictable  heritability  patterns  and  often 
represent  highly  penetrant  phenotypes.  Since  gene 
mapping  for  Mendelian  diseases  has  been  very 
successful, there have been strong expectations for the 
discovery of genetic variations responsible for complex 
diseases.  Very  efficient  and  comprehensive  tools  for 
genome­wide  geno  typing  should  be  the  technical 
solution  and,  although  these  diseases  are  complex  by 
nature, it was commonly believed that we were close to 
resolving the problem by examining each of the variants/
genes  involved.  Since  the  modern  version  of  genome­
wide  association  studies  (GWAS)  was  introduced  in 
2007,  substantial  numbers  of  genetic  risk  factors  have 
been  discovered  for  many  complex  diseases.  However, 
the impact of these factors for the prediction of traits 
remains relatively low. This inability to explain a major 
part of the genetic influence by known genetic variations 
has been defined as ‘missing heritability’.
In  order  to  potentially  explain  ‘the  mystery’,  several 
directions  for  future  research  were  suggested  and 
discussed  at  the  conference.  The  two  main  directions 
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increasing the statistical power of GWAS (for example, 
by extensive meta­analysis); and the study of interactions 
between genes, and between genes and the environment.
Many  GWAS  have  been  published,  with  a  growing 
number  of  observations  and  large  consortia  collecting 
impressive  sets  of  data,  sometimes  with  sample  sizes 
>100,000  individuals.  However,  for  many  phenotypes 
only slight increases in our understanding of heritability 
have been achieved. In the session titled ‘Polygenic traits: 
GWAS  methods  and  results’  it  was  convincingly  pre­
sented by Dr HL Allen et al. (University of Exeter, Exeter, 
UK) and the GIANT consortium that an additional approxi­
mately 10% of heritability variance for adult height can be 
explained by the sum of genetic signals with small effects 
from GWAS.
At  the  session  entitled  ‘Autoimmunity  and  infection’ 
presented by Dr EA Stahl (Brigham and Women’s Hos  pital, 
Boston,  MA,  USA,  and  The  Broad  Institute,  Cambridge, 
MA,  USA)  the  data  on  previously  undiscovered  genetic 
variations obtained from GWAS of rheumatoid arthritis 
suggested  that  a  relatively  high  portion  of  variability 
could be explained. However, it is difficult to pinpoint 
particular risk factors from the set of the candidates with 
small effects in GWAS.
Are interactions the answer?
Multiple  pieces  of  evidence  from  the  presentations  at 
different sessions of the conference indicated that gene­
gene  interactions  contribute  substantially  to  human 
complex diseases.
In  the  plenary  session,  Dr  J  Knight  (King’s  College 
London School of Medicine, London, UK), together with 
the Consortium for Genetic Analysis of Psoriasis and the 
Wellcome Trust Case­Control Consortium II, presented 
important new data on psoriasis susceptibility loci and 
genetic interactions between HLA-C and ERAP1 (endo­
plasmic  reticulum  aminopeptidase  1,  chromosome  5). 
Psoriasis  is  one  of  the  most  common  human 
autoimmune  diseases,  and  discovery  of  genetic 
interactions will serve as an important prototype for the 
study of other complex diseases.
The  session  ‘Polygenic  traits:  GWAS  methods  and 
results’ presented an interesting example of a gene­gene 
interaction, that between APOE and BIN1 (bridging inte­
grator  1,  chromosome  2)  and  CUGBP2  (also  known  as 
CELF2, Elav­like family member 2, chromosome 10). This 
was presented by E Wijsman et al. (University of Wash­
ington School of Medicine at Seattle, Seattle, WA, USA) 
with the National Institute on Aging Genetics Initiative for 
Late­Onset Alzheimer’s Disease/National Cell Repository 
for Alzheimer’s Disease Family Study Group.
In another session entitled ‘Genetic architecture of 
neuro  logical  diseases’,  TA  Thornton­Wells  et  al. 
(Vander  bilt  University’s  School  of  Medicine, 
Nashville,  TN,  USA)  and  The  Alzheimer’s  Disease 
Genetics  Consortium  pre  sented  the  evidence  for 
gene­gene  interactions  in  Alzheimer’s  disease,  and 
these  were  replicated  in  inde  pendent  Alzheimer’s 
Disease  Genetics  Consortium  datasets.  By  using  18 
genes  in  a  multidimensional  reduction  analysis  with 
subsequent  mapping  back  to  the  genes,  ASL 
(argininosuccinate  lyase,  chromosome  7)  and  CPS1 
(carbamoyl­phosphate  synthase  1,  mitochondrial, 
chromosome 2) were found to potentially interact in 
the development of Alzheimer’s disease.
The interest in genetic interactions attracted a great 
deal  of  attention  to  the  session  ‘Translating  GWAS 
statistics  into  biology:  use  of  interaction  studies  and 
functional  information’,  where  the  majority  of  invited 
lectures  were  related  to  gene­gene  and  gene­
environment interactions.
In his lecture entitled ‘Gene­environment interaction 
in the study of human complex diseases: what we can 
learn from rheumatoid arthritis and multiple sclerosis?’ 
Lars  Alfredsson  (Karolinska  Institutet,  Stockholm, 
Sweden) raised several important methodological issues 
in  relation  to  interactions.  By  using  experimental  data 
from  two  common  autoimmune  diseases,  rheumatoid 
arthritis  and  multiple  sclerosis,  Dr  Alfredsson  demon­
strated  the  important  interaction  between  smoking 
behaviour and genetic make­up. Interestingly, substantial 
additional  risk  for  both  diseases  was  detected  in  the 
interaction of smoking with susceptibility alleles from the 
human  leukocyte  antigen  (HLA)  system  locus.  Since 
these alleles are not identical for the two diseases, the 
mechanisms  of  interaction  could  not  be  determined 
easily.  In  rheumatoid  arthritis,  the  major  risk  from 
smoking and HLA shared epitope alleles is known to be 
associated with autoantibody­positive rheumatoid arth­
ritis. It was not surprising that interaction with smoking 
was detected for this particular subgroup of the disease, 
but  was  completely  absent  in  autoantibody­negative 
rheumatoid  arthritis.  In  multiple  sclerosis,  serological 
phenotypes  are  not  well  characterized  in  comparison 
with rheumatoid arthritis, but the lesson from rheuma­
toid  arthritis  is  in  the  evaluation  of  a  more  specific 
subgroup of complex disease rather than analysis of the 
whole  heterogenic  group.  Another  conclusion  was  the 
importance  of  including  environmental  risk  factors  in 
genetic studies of complex diseases.
Marylyn Ritchie (Center for Human Genetic Research 
at Vanderbilt University, Nashville, TN, USA) presented 
the  Biofilter,  an  algorithm  that  was  mentioned  several 
times  in  different  presentations  at  the  conference. 
Biofilter is a bioinformatics approach for generating and 
ranking  biologically  supported  multilocus  models  of 
disease susceptibility. The algorithm automatically accesses 
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cules, data sources for gene relationships to disease, and 
literature­based  data  sources.  These  resources  are 
integrated using a ‘genomic convergence’ approach and 
an implication index that measures the number of data 
sources  that  support  the  model.  In  addition,  Biofilter 
allows  the  investigator  to  include  a  subset  of  disease­
related genes based on previous genetic linkage, genetic 
association,  and  gene  expression  studies.  Dr  Ritchie 
demonstrated examples of successful application of the 
Biofilter in identifying previously unknown interactions 
in human diseases and in quantitative phenotypes.
It can be a bit disheartening to find yourself as the very 
last  lecturer  of  the  very  last  session  of  the  meeting. 
However,  the  interest  in  interaction  studies  remained 
high for this session, which was concluded with my well­
attended  lecture  on  genome­wide  interaction  studies. 
The  data  from  our  group  illustrate  a  new  approach  in 
finding genetic interactions on a genome­wide scale. We 
performed a genome­wide interaction study in rheuma­
toid  arthritis  using  HLA  shared  epitope  alleles  as  an 
anchor in a large population­based study of rheumatoid 
arthritis  in  Sweden,  and  found  several  new  candidate 
genes, which were replicated by similar evaluation in an 
independent study from the USA and were supplemented 
by expression analysis of the genes with highest scores for 
interaction. Using our GEIRA algorithm, a similar study 
could be performed for any disease or categorical trait 
with  a  known  strong  ‘anchor’,  a  robust  and  well­
established risk factor (either genetic or environmental). 
Such strong contributors (usually HLA alleles for auto­
immune diseases), at least in some cases, may represent 
‘the  suzerain  effect’,  when  many  genes  with  a  small 
contribution  for  interaction  with  the  same  factor  may 
each generate a cumulative effect that is non­detectable 
in generic GWAS.
The  end  of  the  meeting  was  illuminated  by  a  very 
inspirational  and  energetic  talk  by  Dr  Francis  Collins 
(Director  of  the  National  Institutes  of  Health  (NIH), 
Bethesda,  MD,  USA)  at  a  special  symposium  entitled 
‘Looking toward a healthier future: perspectives from the 
NIH’.  In  his  lecture,  Dr  Collins  presented  the  current 
vision of opportunities for genetic research and how the 
NIH  is  promoting  this  research.  Substantial  resources 
will be allocated in the future to help elucidate the genetic 
complexity of human diseases, with the goal to initiate 
early prevention programs for individuals at risk.
Similar to previous years, the ASHG meeting was an 
important point in my research schedule, a place to meet 
friends  and  colleagues  from  the  USA  and  many  other 
countries, a time to summarize ideas and to plan new 
projects. This year there was a feeling that we are a few 
steps  further  forward  in  understanding  ‘missing 
heritability’ and that we may soon be able to explain this 
mystery in scientific terms.
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